Neutrophilia Management
Diagnostic Evaluation
- Obtain a complete blood count (CBC) with differential to confirm neutrophilia and assess for left shift (>6% band neutrophils or band count ≥1500/mm³), and to evaluate other cell lines for abnormalities, as recommended by the American College of Physicians 1
- Consider bone marrow aspiration and biopsy if hematologic malignancy is suspected, according to the American Society of Hematology 2
- Genetic testing, including next-generation sequencing (NGS) and whole exome/genome sequencing (WES/WGS), may be considered for suspected hereditary conditions, as recommended by the European League Against Rheumatism 3
- Evaluate for presence of fever (>100°F/37.8°C) or increase of 2°F (1.1°C) over baseline, as recommended by the American Geriatrics Society 4
- Confirm left shift (band neutrophils >6% or band neutrophil count ≥1500/mm³) with a complete blood count with differential, as suggested by the American Geriatrics Society 4
Infection Management
- Administer empiric antibiotics, such as vancomycin plus antipseudomonal antibiotics (cefepime, carbapenem, or piperacillin-tazobactam), for high-risk patients with suspected infection, as recommended by the Infectious Diseases Society of America 1
- Monotherapy with an anti-pseudomonal β-lactam agent, such as piperacillin-tazobactam, is recommended as first-line empiric therapy for patients with neutropenic sepsis, with combination therapy not recommended for routine treatment, according to the IDSA 5, 6
- Administer empiric antibiotics within one hour of recognition of neutropenic sepsis to reduce mortality, as recommended by the Intensive Care Medicine society and the IDSA 7, 5, 6
- Consider adding empirical antifungal therapy if fever persists after 4-7 days of antibiotics, as recommended by the American Society of Clinical Oncology 8
- Empiric antifungal therapy with options including caspofungin or liposomal amphotericin B may be considered if fever persists >96 hours, according to the American Society of Clinical Oncology 9
- Antifungal prophylaxis with fluconazole 400 mg orally daily is recommended until the ANC recovers to > 1000/mm³, as suggested by the IDSA 10
Inflammatory Condition Management
- Target the underlying inflammatory disease and consider IL-1 inhibitors for autoinflammatory disorders, as suggested by the European League Against Rheumatism 3
Hematologic Malignancy Management
- Refer patients with suspected hematologic malignancy to hematology for specific management, as recommended by the American Society of Hematology 2
- Long-term granulocyte colony-stimulating factor (G-CSF) therapy is recommended as the primary treatment for cyclic neutropenia, which significantly reduces infection risk, morbidity, and improves quality of life by shortening periods of neutropenia, according to the American Society of Hematology 11
- The initial starting dose of G-CSF is 3-6 mcg/kg/day subcutaneously, with the goal of maintaining an absolute neutrophil count (ANC) between 1.0-5.0 × 10^9/L to prevent infections 11
- G-CSF can be administered daily or intermittently (every other day) as a long-term therapy 11
Monitoring and Imaging
- Daily assessment of clinical status and fever trends is recommended, according to the Infectious Diseases Society of America 1
- Imaging studies, such as chest radiograph and CT imaging, should be performed as clinically indicated, as recommended by the Infectious Diseases Society of America 1
- Daily assessment of fever trends and clinical status is necessary, with monitoring of complete blood count every 2-3 days, and continue close monitoring until resolution of symptoms and recovery of neutrophil count, as recommended by the Clinical Infectious Diseases guidelines 6
- Obtain blood cultures before starting antibiotics if possible, as recommended by the IDSA and the Clinical Infectious Diseases guidelines 5, 7, 6
- CT imaging of sinuses is not routinely recommended for prolonged febrile neutropenia without localizing symptoms, according to the American College of Radiology 12
- The Multinational Association for Supportive Care in Cancer (MASCC) risk index is used to stratify patients into low-risk (score ≥ 21) or high-risk (score < 21) categories, guiding the intensity of prophylactic and therapeutic measures, with the following scoring system:
| Characteristic | Score |
|---|---|
| Disease burden: absent or mild symptoms | 5 |
| Disease burden: moderate symptoms | 3 |
| Disease burden: severe symptoms | 0 |
| No hypotension (PAS >90 mmHg) | 5 |
| No chronic obstructive pulmonary disease | 4 |
| Solid tumor or lymphoma without prior fungal infection | 4 |
| No dehydration | 3 |
| Outpatient status at the start of fever | 3 |
| Age <60 years | 2 |
Prevention and Patient Education
- Implement infection prevention measures including hand hygiene and dietary restrictions for severe neutropenia (ANC <500/mm³), as recommended by the IDSA 6
- Patients should be educated on the importance of seeking medical attention immediately if they experience a temperature greater than 38.3°C, as advised by the American Society of Clinical Oncology 15
- Daily assessment for potential de-escalation of antibiotics is recommended, and consider de-escalation when the patient becomes afebrile, cultures identify specific pathogens, or there are no clinical signs of infection, according to the IDSA and the Intensive Care Medicine society 5, 7
- The standard duration of antibiotic treatment is 7-10 days, but longer courses may be needed for slow clinical response, undrainable foci of infection, S. aureus bacteremia, or fungal/viral infections, as suggested by the Intensive Care Medicine society and the IDSA 7, 5